Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Select your state to see jurisdictional framework, reporting obligations, and authority links. Substance information above is the same in every state.
A plain-language summary of the cited sources below. Informational only — not medical advice.
Lisdexamfetamine is a stimulant medication most often prescribed to treat Attention Deficit Hyperactivity Disorder (ADHD). In some cases, it may also be prescribed for moderate to severe binge eating disorder in adults when other approaches haven't worked. It works by increasing levels of two brain chemicals—dopamine and noradrenaline—which help with attention, focus, and impulse control.
What makes lisdexamfetamine different from some other stimulants is that it's a prodrug, meaning it starts as an inactive substance and only becomes active once it's inside the body. After your family member takes it, enzymes in their red blood cells break it down into dextroamphetamine, the active stimulant. This conversion takes about an hour, and the effects then last around ten to twelve hours. Because the conversion happens in the blood rather than in the stomach, it's not affected by what they've eaten or how quickly food moves through their system.
Common side effects include reduced appetite, trouble sleeping, dry mouth, headache, and weight loss. These may be noticeable soon after starting the medication or when the dose is adjusted. More serious side effects are less common but do occur. Watch for signs of allergic reactions, unusual changes in mood or behaviour—such as paranoia, hallucinations, or thoughts of self-harm—or new seizures. A very rare but severe skin reaction called Stevens-Johnson Syndrome can also occur.
This medication should not be used in people with certain heart conditions, uncontrolled high blood pressure, overactive thyroid, glaucoma, severe anxiety or agitation, tics or Tourette's syndrome, or a history of alcohol or drug dependence. It must not be taken at the same time as, or within fourteen days of, monoamine oxidase inhibitor medications due to the risk of a dangerous spike in blood pressure. It's also contraindicated in people experiencing severe depression, anorexia nervosa, active psychotic symptoms, or suicidal thinking.
Common off-label uses observed in AU practice — none of these are TGA-approved indications for this substance. If the documented purpose is one of these, the prescription falls outside the TGA-approved set and may sit inside the chemical-restraint frame depending on jurisdiction and context.
These are practitioner observations, not TGA-approved indications. A use being off-label does not by itself imply a regulated restrictive practice; review the documented purpose against the observed function in context.
Tier 4 · ObservationAttention deficit hyperactivity disorder Clinical criteria: Patient must require continuous coverage over 12 hours, AND The treatment must not exceed a maximum daily dose of 70 mg of PBS-subsidised treatment with this drug. Population criteria: Patient must be or have been diagnosed between the ages of 6 and 17 years inclusive; OR Patient must have had a diagnosis of ADHD prior to turning 18 years of age if PBS-subsidised treatment is continuing beyond 18 years of age; OR Patient must have a retrospective diagnosis of ADHD if PBS-subsidised treatment is commencing after turning 18 years of age; OR Patient must have had a retrospective diagnosis of ADHD if PBS-subsidised treatment is continuing in a patient who commenced PBS-subsidised treatment after turning 18 years of age. Treatment criteria: Must be treated by a health practitioner who is any of: (i) a medical practitioner, (ii) a nurse practitioner who is continuing treatment with this medicine (of any strength) that was initiated by a medical practitioner as a PBS benefit. A retrospective diagnosis of ADHD for the purposes of administering this restriction is: (i) the presence of pre-existing childhood symptoms of ADHD (onset during the developmental period, typically early to mid-childhood); and (ii) documentation in the patient's medical records that an in-depth clinical interview with, or, obtainment of evidence from, either a: (a) parent, (b) teacher, (c) sibling, (d) third party, has occurred and which supports point (i) above.
“Amphetamines are non-catecholamine sympathomimetic amines with CNS stimulant activity. The mode of therapeutic action of amphetamine in Attention Deficit Hyperactivity Disorder (ADHD) is not fully established, however it is thought to be due to its ability to block the reuptake of noradrenaline and dopamine into the presynaptic neuron and increase the release of these monoamines into the extraneuronal space.”
“The plasma elimination half-life of lisdexamfetamine typically averaged less than 1 hour in studies of lisdexamfetamine dimesilate in volunteers.”
A plain-language summary of the cited sources below. Informational only — not medical advice.
Lisdexamfetamine is a centrally acting sympathomimetic amine, classified as a Schedule 8 controlled drug. It is an inactive prodrug hydrolysed in red blood cells to dextroamphetamine, the pharmacologically active moiety responsible for therapeutic effect. Dextroamphetamine blocks reuptake of noradrenaline and dopamine into the presynaptic neuron and increases release of these monoamines into the extraneuronal space; the precise mechanism by which this yields benefit in attention deficit hyperactivity disorder remains incompletely established. Conversion from lisdexamfetamine to dextroamphetamine occurs with a half-life of approximately one hour and is not affected by gastrointestinal pH or transit time. TGA-approved indications are treatment of attention deficit hyperactivity disorder and treatment of moderate to severe binge eating disorder in adults when non-pharmacological treatment is unsuccessful or unavailable.
The plasma elimination half-life of lisdexamfetamine itself is less than one hour; the active metabolite dextroamphetamine has a half-life of 10 to 12 hours. Lisdexamfetamine does not inhibit or induce major CYP450 isoforms in vitro. Common adverse effects include decreased appetite, insomnia, dry mouth, headache, and weight loss. Serious adverse effects documented in product information include anaphylactic reaction, psychotic episodes, suicidality and suicidal ideation, seizure, and Stevens-Johnson syndrome. Contraindications include advanced arteriosclerosis, symptomatic cardiovascular disease, moderate to severe hypertension, hyperthyroidism, glaucoma, agitated states, concurrent or recent monoamine oxidase inhibitor use, phaeochromocytoma, tics or Tourette's syndrome, severe depression, anorexia nervosa, psychotic symptoms, suicidal tendency, and known drug dependence or alcohol abuse.
Working under the parallel aged-care framework? Aged-care equivalent →
Curated subset. The full adverse-effect list is in the TGA Product Information; click any citation above to open it.
“Lisdexamfetamine dimesilate was not an in vitro inhibitor of the major human CYP450 isoforms (CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4) in human hepatic microsomal suspensions, nor was it an in vitro inducer of CYP1A2, CYP2B6 or CYP3A4/5 in cultured fresh human hepatocytes.”